SarcopeniaReFitNCT05691166
Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Reduced Muscle Strength
A study testing High-intensity progressive resistance training and Written physical activity guidance in people with Sarcopenia and Aging, run by Norwegian University of Science and Technology at 1 site in Norway.
Trial summary
This study will investigate the effects of 12 months of high-intensity progressive resistance training compared with a control group on fall-rate in older adults with reduced muscle strength. Read more about this study
- Who is it for?
- Ages 80 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia, Aging
- What is being tested?
- High-intensity progressive resistance training and Written physical activity guidance
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 241 participants
- Where
- 1 siteNorway
- Study dates
- 30 Mar 2023to 29 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 80 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Aged 80 years or older
- Low muscular strength (grip strength: <41.6 kg for males and <23.4 kg for females [from 18.09.2024] or chair stand >15 seconds)
- Community-dwelling incl. independent senior housing
- Ambulatory without supervision or physical assistance from another person. Assistive devices such as canes/crutches/walkers allowed.
- Able to see and hear sufficiently to undertake assessments and partake in the planned exercise training.
Who cannot join
- Pre-existing diagnosis of dementia
- Moderate or severe cognitive impairment (score <18 on the Mini-Mental State Examination)
- Living in institutional care
- Non-ambulatory or requiring person or wheelchair to assist when walking
- Degenerative neurological and neuromuscular disease/disorder significantly influencing gait and mobility (e.g. amyotrophic lateral sclerosis [ALS] and Parkinson's disease).
- Amputation (other than toes)
Show all 10Show fewer
- Contraindications to resistance training
- Unstable fracture
- Inability to comply with study requirements
- Currently undertaking progressive resistance training
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Reducing Falls With Progressive Resistance Training (ReFit) for the Oldest Old Adults With Reduced Muscle Strength. A 12-month Randomised Controlled Trial (RCT).
This study will investigate the effects of 12 months of high-intensity progressive resistance training compared with a control group on fall-rate in older adults with reduced muscle strength.
Read the detailed description
Despite the wealth of theoretical benefits, existing literature on resistance training for falls prevention is not conclusive, given the sub-optimal resistance training paradigms, poor study quality, and use of multimodal training interventions, precluding isolation of the resistance training benefits. It is also possible that resistance training benefits for falls reduction will be most evident in those with reduced muscle strength to begin with as a risk factor for their falls. We will therefore conduct a randomised, controlled trial assessing the effects of resistance training reduce falls in the oldest old adults with reduced muscle strength, as well as to increase strength and muscle mass.
Amendment 2023-12-15: The description of the control condition was updated following ethics committee approval. Referral to the general practitioner for follow-up was replaced with provision of written information on current physical activity recommendations for older adults. This change was made to improve acceptability and feasibility of the control condition; the study outcomes and intervention were unchanged.
Amendments: 2024-09-18. We updated the low grip-strength inclusion criterion from [Men:<39.6kg, Women:<21.4kg] to [Men:<41.6kg, Women:23.4kg] based on normative values.
Extension amendment (2025-09-02): With new funding and ethics approval (REK 2022/462261), we added post-trial follow-up at 24 and 36 months to evaluate disability-free survival and the durability of effects on falls and several secondary outcomes. Falls during follow-up are collected via 12-month recall. No changes to interventions or the prespecified 0-12-month primary endpoints.
Title update (2026-09-02): The study title, brief description, and detailed description was revised to describe the eligibility criterion precisely (reduced muscle strength, per the EWGSOP2 probable-sarcopenia criteria) rather than the broader diagnostic label of sarcopenia.
Correction (2026-09-02): The eligibility criteria section displayed the male grip-strength threshold as <41.3 kg; this was a data-entry error. The correct threshold, consistent with the amendment above, is <41.6 kg.
Note (2026-09-02): The Intervention/Treatment field for the Control arm was not updated when the comparator was amended on 2023-12-15, and continued to display the original general-practitioner-referral description. This has been corrected to match the amended comparator described above.
Correction (2026-09-02): This registration previously included two outcome measures that were not implemented in the final study protocol: leg-extension 1RM testing (part of the Dynamic muscular strength measure) and echocardiographic assessment of cardiac structure and function. Dynamic muscular strength in ReFit is assessed using leg-press 1RM only; cardiac imaging was not incorporated into the study procedures.
Clarification (2026-09-02): The intervention/treatment description was updated to reflect a protocol amendment (December 2023) permitting one of the two weekly training sessions to be completed without direct supervision from month 6 onward, provided at least one session per week remains supervised. This does not affect the twice-weekly training frequency or the primary outcome.
Amendment update (2026-09-02): Consistent with the September 2025 amendment above, two outcome measures have been updated to reflect assessments added at that time. The outcome measure previously registered as "Protein intake" has been renamed "Dietary intake" and its description broadened to reflect that it captures both 24-hour dietary recall (Norkost 4 protocol) and the Protein Screener 55+, with the 6-month timepoint added. The outcome measure "Physical activity" has been renamed "Physical activity and muscle-strengthening exercise behaviour" and its description broadened to include the Muscle-Strengthening Exercise Questionnaire (MSEQ) short form, alongside the previously registered physical activity questions. As these assessments were introduced during the trial, data are not available for all participants at all timepoints.
Correction (2026-09-02): The Musculoskeletal pain outcome measure previously included a 10-cm visual analogue scale for lower back and neck pain specifically; this item is not used and has been removed. The description has been updated to include the pain-intensity and interference items adapted from the Norwegian Short Form of the Musculoskeletal Instrument for Screening Symptoms (NOSF-Miss), and timepoints have been corrected to 6, 12, 24 and 36 months (previously registered as 6 and 12 months only).
- Conditions
- Sarcopenia, Aging
- Being tested
- High-intensity progressive resistance training, Written physical activity guidance
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-intensity progressive resistance trainingBehavioural
Twice-weekly high-intensity progressive resistance training for 12 months, delivered at community-based fitness centres. Both weekly sessions are supervised during the first 6 months; from month 6 onward, one session per week may be completed without direct supervision, provided at least one session per week remains supervised.
Written physical activity guidanceOther
Participants receive a booklet containing Norway's current physical activity recommendations for older adults, including instructions for seven exercises intended to reduce fall risk.
| Study group | Role | What they receive |
|---|---|---|
| Progressive resistance training | Experimental | Twice weekly high-intensity progressive resistance training for 12 months Receives: Behavioral: High-intensity progressive resistance training |
| Control | Active comparator | Participants randomised to the control group receive a booklet containing Norway's current recommendations for physical activity for older adults. These recommendations mean ≥150 minutes of moderate-intensity or ≥75 minutes of vigorous-intensity physical activity per week and two to three weekly balance and resistance training sessions. The booklet also includes pictures and instructions for seven exercises to help prevent falls. Receives: Other: Written physical activity guidance |
What is being measured
The primary outcome is the main question the study is designed to answer.
Falls
Relative risk for falls, fall rate per person years. Self-report.
Measured: 12 months
Secondary outcomes (29)
Falls
Relative risk for falls, fall rate per person years. Self-report.
Measured: 6 months
Falls
Number of falls, number of fallers/nonfallers/frequent fallers, and time to first fall. Self-report.
Measured: 6, 12, 24, and 36 months.
Falls requiring medical attention
Number of falls requiring medical attention. Collected via self-report and ascertained by linkage to the Norwegian Patient Registry and medical journals with the use of unique 11-digit Norwegian national identification number for each participant.
Measured: 6, 12, 24, 36 months
Fall-related injuries
Classified according to the International Classification of Diseases, 11th revision, classification system. Peripheral fracture rate per person-years, number of peripheral fractures, number of people sustaining peripheral fractures, and number of people sustaining multiple events. Collected via self-report and ascertained by linkage to the Norwegian Patient Registry and medical journals with the use of unique 11-digit Norwegian national identification number for each participant.
Measured: 6, 12, 24, 36 months
Dynamic muscular strength
1-repetition maximum leg press
Measured: 6 and 12 months
Grip strength
Maximal isometric handgrip strength
Measured: 6, 12, 24, 36 months
Muscular power
Muscular power assessed using a force platform installed on a leg press machine
Measured: 6 and 12 months
Physical performance
Physical performance using the Short Physical Performance Battery
Measured: 6, 12, 24, 36 months
Balance
Static and dynamic balance using the Mini-Balance Evaluation Systems Test (BESTest)
Measured: 6, 12, 24, 36 months
Stature
Stretch stature using a wall-mounted stadiometer
Measured: 6, 12, 24, 36 months
Body mass
Body mass estimated using multi-frequency bioelectrical impedance analysis
Measured: 6, 12, 24, 36 months
Body composition
Estimated using multi-frequency bioelectrical impedance analysis. Fat mass, skeletal muscle mss, appendicular skeletal muscle mass.
Measured: 6, 12, 24, 36 months
Circumferences
Waist, arm, and calf circumference
Measured: 6 and 12 months
Resting blood pressure and resting heart rate
Systolic and diastolic blood pressure, and resting heart rate measured after 5 minutes of seated resting using an automated blood pressure device
Measured: 6, 12, 24, 36 months
Orthostatic blood pressure
Systolic and diastolic blood pressure response 1, and 3-min after standing up
Measured: 6, 12, 24, 36 months
Physical activity and muscle-strengthening exercise behaviour
Habitual physical activity level is assessed using three questions on the frequency, duration, and intensity of physical activity, previously validated and used in the Trøndelag Health Study. Muscle-strengthening exercise behaviour is assessed using the Muscle-Strengthening Exercise Questionnaire (MSEQ) short form.
Measured: 6, 12, 24, 36 months
Health-related quality of life
Health-related quality of life assessed using the 12-item Short-form health survey
Measured: 6, 12, 24, 36 months
Fear of falling
Fear of falling assessed using the Falls Efficacy Scale-International
Measured: 6, 12, 24, 36 months
Cognitive function
Cognitive function evaluated using The Mini Mental State Examination
Measured: 6 and 12 months
Depression
Levels of depression measured via the Geriatric Depression Scale.
Measured: 6, 12, 24, 36 months
Frailty
Physical frailty assessed according to Fried's frailty phenotype
Measured: 6, 12, 24, 36 months
Nutritional status
Nutritional status assessed using the Mini-nutritional Assessment Short form.
Measured: 6, 12, 24, 36 months
Sleep quality
Sleep quality assessed using the Pittsburgh Sleep Quality Index
Measured: 6, 12, 24, 36 months
Hospital admissions
Information about hospitalisations due to falls and fall-related injuries will be collected by means of electronic linkage to the Norwegian Patient Registry and medical journals with the use of a unique 11-digit Norwegian national identification number for each participant.
Measured: 0-12 months and 0-36 months
Use of primary health care, community care, and assistive technology
Use of primary health care (general practitioner, emergency room, physiotherapist, and chiropractor), community care, and assistive technology during the study will be collected by linkage to the Norwegian Municipal Patient and User Register (KPR) database with the use of a unique 11-digit Norwegian national identification number for each participant.
Measured: 0-12 months and 0-36 months
Use of prescription drugs
Use of prescription drugs during the study will be collected by linkage to the Norwegian Prescribed Drug Registry with the use of a unique 11-digit Norwegian national identification number for each participant.
Measured: 12 months
Disability-free survival (DFS)
DFS is defined as time from randomization to the first occurrence of: (i) death from any cause; (ii) incident dementia; or (iii) incident ADL disability. Participants with dementia or ADL disability at baseline are excluded from the DFS analysis.
Death: ascertained by linkage to the Norwegian Cause of Death Registry.
Incident ADL disability: score of 3-5 any of the six primary ADLs (Physical Self-Maintenance Scale) or a score of 0 for any of the five instrumental ADLs (Lawton IADL Scale). If ADL status cannot be obtained, admission to long-term nursing care (national registries) will be used as a proxy for disability.
Incident dementia: registry/clinical diagnosis (ICD-10 F00-F03, G30, or equivalent codes in national registries). Exploratory supplement: MoCA assessed at 24/36 months; dementia defined as MoCA z-score ≤ -2.0 (age/education-adjusted).
Measured: Baseline to 36 months post-randomisation
Healthcare and implementation costs
Intervention costs (resistance training and control), prescription medication, and health and care service utilisation during the 12-month intervention period. Costs for the training intervention include fitness centre membership fees and instructor labour costs (time worked + overheads). We will not consider potential travel costs for participants. We will obtain expenses related to prescription medication and health care service utilisation by linking participant data with data from the Norwegian Prescribed Drug Registry, the Norwegian Patient Registry (specialist health services), and the Municipal Patient and User Register (primary care, care services, physiotherapist, and chiropractor). We focus only on implementation costs, thus disregarding research protocol costs (e.g. recruitment).
Measured: 0-12 months
Quality-Adjusted Life-Years (QALY's)
We use the 12-item short-form health survey (SF-12) to assess health-related quality of life across eight areas, with scores summed into a physical component summary score and a mental component summary score, ranging from 0 to 100, with higher scores indicating a better quality of life.32 Next, we'll convert the SF-12 scores into SF-6D utility scores using the equation by Brazier and Roberts (2004).33 The utility scores range from 0 (equivalent to death) to 1 (equivalent to perfect health). Finally, we'll calculate QALYs for the 12-month intervention period by linearly interpolating SF-6D utility scores for baseline, six, and 12 months
Measured: 0-12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jan 2023
- Study start30 Mar 2023
- Primary completion29 Sep 2026 (estimated)
- Study completion29 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 241 participants (actual)
Sponsor and investigators
- Lead sponsor
- Norwegian University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jonathan Berg, PhD, Principal investigator, Norwegian University of Science and TechnologyØivind Rognmo, PhD, Study director, Norwegian University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05691166
- Sponsor's protocol ID
- 2022/462261
- Acronym
- ReFit
- Status last verified
- Sep 2026
- First submitted
- 16 Dec 2022
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Svinoy OE, Hilde G, Bergland A, Strand BH. Reference values for Jamar+ digital dynamometer hand grip strength in healthy adults and in adults with non-communicable diseases or osteoarthritis: the Norwegian Tromso study 2015-2016. Eur J Ageing. 2023 Nov 24;20(1):44. doi: 10.1007/s10433-023-00791-w.
PubMed 37999814
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reducing Falls With Progressive Resistance Training (ReFit) for the Oldest Old Adults With Reduced Muscle Strength. A 12-month Randomised Controlled Trial (RCT).
- ClinicalTrials.gov ID
- NCT05691166
- Acronym / sponsor ID
- ReFit / 2022/462261
- Conditions
- Sarcopenia, Aging
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 241 participants (actual)
- Lead sponsor
- Norwegian University of Science and TechnologyUniversity, hospital or other
- Study start
- 30 Mar 2023 (actual)
- Primary completion
- 29 Sep 2026 (estimated)
- Study completion
- 29 Sep 2028 (estimated)
- First posted
- 19 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigate the effects of 12 months of high-intensity progressive resistance training compared with a control group on fall-rate in older adults with reduced muscle strength.
Detailed description
Despite the wealth of theoretical benefits, existing literature on resistance training for falls prevention is not conclusive, given the sub-optimal resistance training paradigms, poor study quality, and use of multimodal training interventions, precluding isolation of the resistance training benefits. It is also possible that resistance training benefits for falls reduction will be most evident in those with reduced muscle strength to begin with as a risk factor for their falls. We will therefore conduct a randomised, controlled trial assessing the effects of resistance training reduce falls in the oldest old adults with reduced muscle strength, as well as to increase strength and muscle mass.
Amendment 2023-12-15: The description of the control condition was updated following ethics committee approval. Referral to the general practitioner for follow-up was replaced with provision of written information on current physical activity recommendations for older adults. This change was made to improve acceptability and feasibility of the control condition; the study outcomes and intervention were unchanged.
Amendments: 2024-09-18. We updated the low grip-strength inclusion criterion from [Men:<39.6kg, Women:<21.4kg] to [Men:<41.6kg, Women:23.4kg] based on normative values.
Extension amendment (2025-09-02): With new funding and ethics approval (REK 2022/462261), we added post-trial follow-up at 24 and 36 months to evaluate disability-free survival and the durability of effects on falls and several secondary outcomes. Falls during follow-up are collected via 12-month recall. No changes to interventions or the prespecified 0-12-month primary endpoints.
Title update (2026-09-02): The study title, brief description, and detailed description was revised to describe the eligibility criterion precisely (reduced muscle strength, per the EWGSOP2 probable-sarcopenia criteria) rather than the broader diagnostic label of sarcopenia.
Correction (2026-09-02): The eligibility criteria section displayed the male grip-strength threshold as <41.3 kg; this was a data-entry error. The correct threshold, consistent with the amendment above, is <41.6 kg.
Note (2026-09-02): The Intervention/Treatment field for the Control arm was not updated when the comparator was amended on 2023-12-15, and continued to display the original general-practitioner-referral description. This has been corrected to match the amended comparator described above.
Correction (2026-09-02): This registration previously included two outcome measures that were not implemented in the final study protocol: leg-extension 1RM testing (part of the Dynamic muscular strength measure) and echocardiographic assessment of cardiac structure and function. Dynamic muscular strength in ReFit is assessed using leg-press 1RM only; cardiac imaging was not incorporated into the study procedures.
Clarification (2026-09-02): The intervention/treatment description was updated to reflect a protocol amendment (December 2023) permitting one of the two weekly training sessions to be completed without direct supervision from month 6 onward, provided at least one session per week remains supervised. This does not affect the twice-weekly training frequency or the primary outcome.
Amendment update (2026-09-02): Consistent with the September 2025 amendment above, two outcome measures have been updated to reflect assessments added at that time. The outcome measure previously registered as "Protein intake" has been renamed "Dietary intake" and its description broadened to reflect that it captures both 24-hour dietary recall (Norkost 4 protocol) and the Protein Screener 55+, with the 6-month timepoint added. The outcome measure "Physical activity" has been renamed "Physical activity and muscle-strengthening exercise behaviour" and its description broadened to include the Muscle-Strengthening Exercise Questionnaire (MSEQ) short form, alongside the previously registered physical activity questions. As these assessments were introduced during the trial, data are not available for all participants at all timepoints.
Correction (2026-09-02): The Musculoskeletal pain outcome measure previously included a 10-cm visual analogue scale for lower back and neck pain specifically; this item is not used and has been removed. The description has been updated to include the pain-intensity and interference items adapted from the Norwegian Short Form of the Musculoskeletal Instrument for Screening Symptoms (NOSF-Miss), and timepoints have been corrected to 6, 12, 24 and 36 months (previously registered as 6 and 12 months only).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Progressive resistance training | Experimental | Behavioral: High-intensity progressive resistance trainingTwice weekly high-intensity progressive resistance training for 12 months |
| Control | Active comparator | Other: Written physical activity guidanceParticipants randomised to the control group receive a booklet containing Norway's current recommendations for physical activity for older adults. These recommendations mean ≥150 minutes of moderate-intensity or ≥75 minutes of vigorous-intensity physical activity per week and two to three weekly balance and resistance training sessions. The booklet also includes pictures and instructions for seven exercises to help prevent falls. |
Who may qualify
- Ages
- 80 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (5 listed)
- Aged 80 years or older
- Low muscular strength (grip strength: <41.6 kg for males and <23.4 kg for females [from 18.09.2024] or chair stand >15 seconds)
- Community-dwelling incl. independent senior housing
- Ambulatory without supervision or physical assistance from another person. Assistive devices such as canes/crutches/walkers allowed.
- Able to see and hear sufficiently to undertake assessments and partake in the planned exercise training.
Key exclusion criteria (10 listed)
- Pre-existing diagnosis of dementia
- Moderate or severe cognitive impairment (score <18 on the Mini-Mental State Examination)
- Living in institutional care
- Non-ambulatory or requiring person or wheelchair to assist when walking
- Degenerative neurological and neuromuscular disease/disorder significantly influencing gait and mobility (e.g. amyotrophic lateral sclerosis [ALS] and Parkinson's disease).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-intensity progressive resistance trainingTwice-weekly high-intensity progressive resistance training for 12 months, delivered at community-based fitness centres. Both weekly sessions are supervised during the first 6 months; from month 6 onward, one session per week may be completed without direct supervision, provided at least one session per week remains supervised. | Behavioural | Progressive resistance training |
| Written physical activity guidanceParticipants receive a booklet containing Norway's current physical activity recommendations for older adults, including instructions for seven exercises intended to reduce fall risk. | Other | Control |
Primary outcome
Falls
Time frame: 12 months
Relative risk for falls, fall rate per person years. Self-report.
29 secondary outcomes
Falls
Time frame: 6 months
Falls
Time frame: 6, 12, 24, and 36 months.
Falls requiring medical attention
Time frame: 6, 12, 24, 36 months
Fall-related injuries
Time frame: 6, 12, 24, 36 months
Dynamic muscular strength
Time frame: 6 and 12 months
Grip strength
Time frame: 6, 12, 24, 36 months
Muscular power
Time frame: 6 and 12 months
Physical performance
Time frame: 6, 12, 24, 36 months
Balance
Time frame: 6, 12, 24, 36 months
Stature
Time frame: 6, 12, 24, 36 months
Body mass
Time frame: 6, 12, 24, 36 months
Body composition
Time frame: 6, 12, 24, 36 months
Circumferences
Time frame: 6 and 12 months
Resting blood pressure and resting heart rate
Time frame: 6, 12, 24, 36 months
Orthostatic blood pressure
Time frame: 6, 12, 24, 36 months
Physical activity and muscle-strengthening exercise behaviour
Time frame: 6, 12, 24, 36 months
Health-related quality of life
Time frame: 6, 12, 24, 36 months
Fear of falling
Time frame: 6, 12, 24, 36 months
Cognitive function
Time frame: 6 and 12 months
Depression
Time frame: 6, 12, 24, 36 months
Frailty
Time frame: 6, 12, 24, 36 months
Nutritional status
Time frame: 6, 12, 24, 36 months
Sleep quality
Time frame: 6, 12, 24, 36 months
Hospital admissions
Time frame: 0-12 months and 0-36 months
Use of primary health care, community care, and assistive technology
Time frame: 0-12 months and 0-36 months
Use of prescription drugs
Time frame: 12 months
Disability-free survival (DFS)
Time frame: Baseline to 36 months post-randomisation
Healthcare and implementation costs
Time frame: 0-12 months
Quality-Adjusted Life-Years (QALY's)
Time frame: 0-12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Background: PubMed 37999814Svinoy OE, Hilde G, Bergland A, Strand BH. Reference values for Jamar+ digital dynamometer hand grip strength in healthy adults and in adults with non-communicable diseases or osteoarthritis: the Norwegian Tromso study 2015-2016. Eur J Ageing. 2023 Nov 24;20(1):44. doi: 10.1007/s10433-023-00791-w.
Related trials for Sarcopenia
Active, not recruitingObservational study
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
Primary Sjögren Syndrome, Sarcopenia
Not yet recruiting
PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty
Frailty, Sarcopenia
Recruiting
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
Recruiting
Effects of a Community-based Multicomponent Physical Exercise Program on Physical Function, Frailty, and Sarcopenia in Older Adults From the Municipality of Santoña: a Quasi-experimental Study.
Frailty/Sarcopenia, Frailty in Older Adults
Not yet recruiting
Creatine and Muscle Health in Madrid's Walking Footballers.
Muscle Adaptation, Body Composition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathan Berg, PhD principal investigator
Norwegian University of Science and Technology
Øivind Rognmo, PhD study director
Norwegian University of Science and Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High-intensity progressive resistance training and Written physical activity guidance in people with Sarcopenia and Aging, run by Norwegian University of Science and Technology at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Falls (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05691166, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.